pSivida Articles
Another FDA rejection for Alimera’s DME drug Iluvien
14 November 2011
pSivida to receive up to $168 million plus royalties under revised deal with Pfizer; starts new clinical study
15 June 2011
US FDA approves Novartis’ Amturnide for BP and Watson’s chewable oral contraceptive, but delays Alimera’s Iluvien
24 December 2010
Showing 1-5 of 5 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
